Pharmaceutical Approval Update.
Pharmaceutical Approval Update.
P T. 2019 Sep;44(9):527-529
Authors: Choy M
Abstract
Alpelisib (Piqray) for HR-positive/HER2-negative, PIK3CA-mutated, advanced/ metastatic breast cancer; polatuzumab vedotin-piiq (Polivy) for diffuse large B-cell lymphoma; and eculizumab (Soliris) for neuromyelitis optica spectrum disorder.
PMID: 31485143 [PubMed]
Source: P and T - Category: Drugs & Pharmacology Tags: P T Source Type: research
More News: Brain | Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | HER2 | Lymphoma | Neurology